An observational study on the empiric use of cefpirome in febrile neutropenia

Journal of Microbiology, Immunology and Infection

Volumn 40, Issue 1, 2007, Pages 62-67

  Su, Yu Chieh ^a   Sheu, Yu Tsan ^a   Peng, Ming Yieh ^b   Yeh, Kuo Ming ^b   Huang, Chao Yuan ^c   Wang, Shao Mon ^c   Chang, Yi Fang ^d   Chang, Ming Chih ^d   Wu, Ming Fang ^e   Tsao, Shih Ming ^a,e  

^a BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d MACKAY MEMORIAL HOSPITAL   (Taiwan)

^e CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Bacterial infections; Cephalosporins; Fever; Neutropenia; Treatment outcome

Indexed keywords

CEFPIROME; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM ISOLATION; BODY TEMPERATURE MEASUREMENT; CLINICAL EVALUATION; CLINICAL TRIAL; DRUG EFFICACY; FEBRILE NEUTROPENIA; FEMALE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; MICROBIOLOGICAL EXAMINATION; MORTALITY; MULTICENTER STUDY; NEUTROPHIL COUNT; OBSERVATIONAL STUDY; RECOMMENDED DRUG DOSE; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; BIOASSAY; FEVER; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE COUNT; MIDDLE AGED; NEUTROPENIA; NEUTROPHIL; PATHOLOGY; TAIWAN; TIME;

ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; ENDPOINT DETERMINATION; FEVER; HUMANS; INJECTIONS, INTRAVENOUS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; NEUTROPENIA; NEUTROPHILS; TAIWAN; TIME FACTORS; TREATMENT OUTCOME;

EID: 34347379985     PISSN: 16841182     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Glauser M. Empiric therapy of bacterial infections in patients with severe neutropenia. Diagn Microbiol Infect Dis. 1998;31: 467-72.
2. Marie JP, Vekhoff A, Pico JL, Guy H, Andremont A, Richet H. Neutropenic infections: a review of the French Febrile Aplasia Study Group trials in 608 febrile neutropenic patients. J Antimicrob Chemother. 1998;41(Suppl D):57-64.
3. Sader HS, Jones RN. Historical overview of the cephalosporin spectrum: four generations of structural evolution. Antimicrobic Newsletter. 1992;8:75-84.
4. Cheng AF, Ling TK, Lam AW, Fung KS, Wise R. The antimicrobial activity and beta-lactamase stability of cefpirome, a new fourth-generation cephalosporin in comparison with other agents. J Antimicrob Chemother. 1993;31:699-709.
5. Jones RN. Important and emerging beta-lactamase-mediated resistances in hospital-based pathogens: the Amp C enzymes. Diagn Microbiol Infect Dis. 1998;31:461-6.
6. Matron A, Carratala J, Alcaide A, Fernandez-Sevilla A, Gudiol F. High rates of resistance to cephalosporins among viridans-group streptococci causing bacteraemia in neutropenic cancer patients. J Antimicrob Chemother. 2001;47:87-91.
7. Wiseman LR, Lamb HM. Cefpirome. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy in the treatment of severe nosocomial infections and febrile neutropenia. Drugs. 1997;54:117-40.
8. Pierard D, Emmerechts K, Lauwers S. Comparative in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology units. Belgian Multicentre Study Group.. J Antimicrob Chemother. 1998;41:443-50.
9. Friedland IR, Sultan E, Lehr KH, Lenfant B. Concentrations of cefpirome in cerebrospinal fluid of children with bacterial meningitis after a single intravenous dose. Antimicrob Agents Chemother. 1998;42:199-201.
10. Wolff M. Comparison of strategies using cefpirome and ceftazidime for empiric treatment of pneumonia in intensive care patients. The Cefpirome Pneumonia Study Group. Antimicrob Agents Chemother. 1998;42:28-36.
11. Fang CT, Chen YC, Lin SF, Shau WY, Liu CJ, Sheng WH, et al: Safety and efficacy of cefpirome in comparison with ceftazidime in Chinese patients with sepsis due to bacterial infections. Chemotherapy. 2000;46:371-8.
12. Bauduer F, Cousin T, Boulat O, Rigal-Huguet F, Molina L, Fegueux N, et al. A randomized prospective multicentre trial of cefpirome versus piperacillin-tazobactam in febrile neutropenia. Leuk Lymphoma 2001;42:379-86.
13. Update BNHI Price of Taiwan. Bureau of National Health Insurance; 2005.
14. Timmers GJ, van Vuurden DG, Swart EL, Simoons-Smit AM, Huijgens PC. Cefpirome as empirical treatment for febrile neutropenia in patients with hematologic malignancies. Haematologica. 2005;90:1005-6.
15. Infectious Disease Society of Taiwan; Hematology Society of Taiwan; Medical Foundation in Memory of Dr. Deh-Lin Cheng; Foundation of Professor Wei-Chuan Hsieh for Infectious Disease Research and Education; and CY Lee's Research Foundation for Pediatric Infectious Diseases and Vaccine. Guidelines for the use of antimicrobial agents in patients with febrile neutropenia in Taiwan. J Microbiol Immunol Infect. 2005;38:455-7.